drugset / Trial / NCT00266630

Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder

NCT00266630

Phase 3 Completed 139 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The efficacy and safety of the extended treatment to patients with most recent episode manic or mixed who completed previous double blind study (F1D-JE-BMAC \[Study BMAC\]) will be examined.

Timeline

Start
2005-11
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 5 mg Oral
Subject Olanzapine Small molecule 20 mg Oral
Background Carbamazepine Small molecule
Background Lithium Unknown
Background Valproate Small molecule